Vonlerolizumab
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134) . Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models[1].
Product Specifications
CAS Number
[1638935-72-4]
Product Name Alternative
Pogalizumab; MOXR 0916
UNSPSC
12352203
Target
Orexin Receptor (OX Receptor)
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vonlerolizumab.html
Purity
99.70
Solubility
10 mM in DMSO
Smiles
[Vonlerolizumab]
Molecular Weight
(145.26 kDa)
References & Citations
[1]Holay N, et al. INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering. J Immunother Cancer. 2025 May 21;13 (5) :e011524.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
46941121 3x 1.0µg DNA
TMEM173 CRISPRa sgRNA lentivector (set of three targets)(Human)
Sign In for Pricing
View Details 
K4101807 1.0 µg DNA
Lpxn sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)
Sign In for Pricing
View Details 050098-01 10 µg
Testicular Receptor 2 (TR2), Recombinant, Human, His-Tag
Sign In for Pricing
View Details